$RFL
Rafael Holdings Inc

2023 Q4 Form 10-Q Financial Statement

#000121390023095748 Filed on December 14, 2023

View on sec.gov

Income Statement

Concept 2023 Q4 2023 Q3 2022 Q4
Revenue $68.00K $70.00K $70.00K
YoY Change -2.86% 1.45% -93.18%
Cost Of Revenue $249.0K
YoY Change -70.18%
Gross Profit -$179.0K
YoY Change -193.72%
Gross Profit Margin -255.71%
Selling, General & Admin $2.040M $1.400M $3.109M
YoY Change -34.38% -54.07% -75.88%
% of Gross Profit
Research & Development $489.0K $1.270M $2.081M
YoY Change -76.5% -31.02% -3.34%
% of Gross Profit
Depreciation & Amortization $17.00K $20.00K $22.00K
YoY Change -22.73% -101.87% -94.24%
% of Gross Profit
Operating Expenses $489.0K $2.680M $5.190M
YoY Change -90.58% -45.38% -89.77%
Operating Profit -$2.478M -$5.142M
YoY Change -51.81% -89.62%
Interest Expense -$1.153M $4.060M
YoY Change 2003.63%
% of Operating Profit
Other Income/Expense, Net $93.00K
YoY Change
Pretax Income -$3.538M $1.460M -$5.202M
YoY Change -31.99% -131.43% -95.96%
Income Tax $6.000K $0.00 $5.000K
% Of Pretax Income 0.0%
Net Earnings -$3.638M $1.220M -$5.207M
YoY Change -30.13% -125.5% -95.35%
Net Earnings / Revenue -5350.0% 1742.86% -7438.57%
Basic Earnings Per Share -$0.15 $0.07
Diluted Earnings Per Share -$0.16 $0.05 $0.07
COMMON SHARES
Basic Shares Outstanding 23.64M shares 23.02M shares
Diluted Shares Outstanding 23.64M shares 23.02M shares

Balance Sheet

Concept 2023 Q4 2023 Q3 2022 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $72.09M $79.21M $93.19M
YoY Change -22.64% 25.27% 28.73%
Cash & Equivalents $13.20M $21.50M $22.17M
Short-Term Investments $58.89M $57.71M $71.01M
Other Short-Term Assets $2.866M $900.0K $1.428M
YoY Change 100.7% -97.98% -73.69%
Inventory
Prepaid Expenses
Receivables $245.0K $245.0K $306.0K
Other Receivables $1.858M $1.900M $0.00
Total Short-Term Assets $77.47M $82.94M $94.92M
YoY Change -18.39% -23.45% 20.88%
LONG-TERM ASSETS
Property, Plant & Equipment $1.671M $1.695M $1.751M
YoY Change -4.57% -4.24% -95.92%
Goodwill
YoY Change
Intangibles $0.00
YoY Change
Long-Term Investments $14.75M $12.60M $4.958M
YoY Change 197.46% 140.41% -16.76%
Other Assets $42.00K $9.000K $11.00K
YoY Change 281.82% -99.35% -99.25%
Total Long-Term Assets $18.04M $15.89M $8.295M
YoY Change 117.43% 59.31% -84.01%
TOTAL ASSETS
Total Short-Term Assets $77.47M $82.94M $94.92M
Total Long-Term Assets $18.04M $15.89M $8.295M
Total Assets $95.50M $98.83M $103.2M
YoY Change -7.47% -16.47% -20.85%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $494.0K $333.0K $1.394M
YoY Change -64.56% -40.96% 16.46%
Accrued Expenses $325.0K $763.0K $1.602M
YoY Change -79.71% -59.31% 23.99%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change -100.0% -100.0%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $934.0K $2.145M $3.206M
YoY Change -70.87% -89.8% -81.43%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $56.00K $55.00K $44.00K
YoY Change 27.27% -37.5% -45.68%
Total Long-Term Liabilities $56.00K $55.00K $44.00K
YoY Change 27.27% -37.5% -45.68%
TOTAL LIABILITIES
Total Short-Term Liabilities $934.0K $2.145M $3.206M
Total Long-Term Liabilities $56.00K $55.00K $44.00K
Total Liabilities $990.0K $2.200M $3.250M
YoY Change -69.54% -89.58% -89.74%
SHAREHOLDERS EQUITY
Retained Earnings -$171.0M -$167.3M -$163.9M
YoY Change 4.34% 1.13%
Common Stock $265.5M $264.0M $8.000K
YoY Change 3318487.5% 3300025.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $98.21M $100.3M $103.4M
YoY Change
Total Liabilities & Shareholders Equity $95.50M $98.83M $103.2M
YoY Change -7.47% -16.47% -20.85%

Cashflow Statement

Concept 2023 Q4 2023 Q3 2022 Q4
OPERATING ACTIVITIES
Net Income -$3.638M $1.220M -$5.207M
YoY Change -30.13% -125.5% -95.35%
Depreciation, Depletion And Amortization $17.00K $20.00K $22.00K
YoY Change -22.73% -101.87% -94.24%
Cash From Operating Activities -$2.133M -$1.450M -$2.549M
YoY Change -16.32% -23.76% -60.63%
INVESTING ACTIVITIES
Capital Expenditures $0.00
YoY Change -100.0%
Acquisitions
YoY Change
Other Investing Activities -$6.786M $7.410M $13.94M
YoY Change -148.67% -214.67% -151.88%
Cash From Investing Activities -$6.786M $7.410M $13.94M
YoY Change -148.67% -216.2% -151.83%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $79.00K
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities $807.0K -40.00K -$15.01M
YoY Change -105.38% -100.67% -115.33%
NET CHANGE
Cash From Operating Activities -$2.133M -1.450M -$2.549M
Cash From Investing Activities -$6.786M 7.410M $13.94M
Cash From Financing Activities $807.0K -40.00K -$15.01M
Net Change In Cash -$8.301M 5.920M -$3.704M
YoY Change 124.11% -359.42% -105.74%
FREE CASH FLOW
Cash From Operating Activities -$2.133M -$1.450M -$2.549M
Capital Expenditures $0.00
Free Cash Flow -$1.450M
YoY Change -27.03%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022Q4 rfl Equity In Losses Of Day Three Labs Inc
EquityInLossesOfDayThreeLabsInc
usd
CY2023Q4 us-gaap Discontinued Operation Income Loss From Discontinued Operation During Phase Out Period Net Of Tax
DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodNetOfTax
usd
CY2023Q4 dei Document Type
DocumentType
10-Q
CY2023Q4 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2023Q4 dei Document Period End Date
DocumentPeriodEndDate
2023-10-31
CY2023Q4 dei Document Transition Report
DocumentTransitionReport
false
CY2023Q4 dei Entity File Number
EntityFileNumber
000-55863
CY2023Q4 dei Entity Registrant Name
EntityRegistrantName
RAFAEL HOLDINGS, INC.
CY2023Q4 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2023Q4 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
82-2296593
CY2023Q4 dei Entity Address Address Line1
EntityAddressAddressLine1
520 Broad Street
CY2023Q4 dei Entity Address City Or Town
EntityAddressCityOrTown
Newark
CY2023Q4 dei Entity Address State Or Province
EntityAddressStateOrProvince
NJ
CY2023Q4 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
07102
CY2023Q4 dei City Area Code
CityAreaCode
(212)
CY2023Q4 dei Local Phone Number
LocalPhoneNumber
658-1450
CY2023Q4 dei Security12b Title
Security12bTitle
Class B common stock, par value $0.01 per share
CY2023Q4 dei Trading Symbol
TradingSymbol
RFL
CY2023Q4 dei Security Exchange Name
SecurityExchangeName
NYSE
CY2023Q4 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2023Q4 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2023Q4 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2023Q4 dei Entity Small Business
EntitySmallBusiness
true
CY2023Q4 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2023Q4 dei Entity Shell Company
EntityShellCompany
false
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
13197000 usd
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
21498000 usd
CY2023Q4 us-gaap Assets Held For Sale Not Part Of Disposal Group Current
AssetsHeldForSaleNotPartOfDisposalGroupCurrent
58894000 usd
CY2023Q3 us-gaap Assets Held For Sale Not Part Of Disposal Group Current
AssetsHeldForSaleNotPartOfDisposalGroupCurrent
57714000 usd
CY2023Q4 us-gaap Interest Receivable Current
InterestReceivableCurrent
420000 usd
CY2023Q3 us-gaap Interest Receivable Current
InterestReceivableCurrent
387000 usd
CY2023Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
245000 usd
CY2023Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
245000 usd
CY2023Q4 us-gaap Accounts And Other Receivables Net Current
AccountsAndOtherReceivablesNetCurrent
231000 usd
CY2023Q3 us-gaap Accounts And Other Receivables Net Current
AccountsAndOtherReceivablesNetCurrent
213000 usd
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2866000 usd
CY2023Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
914000 usd
CY2023Q3 us-gaap Equity Securities Fv Ni
EquitySecuritiesFvNi
294000 usd
CY2023Q4 us-gaap Assets Current
AssetsCurrent
77466000 usd
CY2023Q3 us-gaap Assets Current
AssetsCurrent
82941000 usd
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1671000 usd
CY2023Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1695000 usd
CY2023Q4 us-gaap Deferred Tax Assets In Process Research And Development
DeferredTaxAssetsInProcessResearchAndDevelopment
1575000 usd
CY2023Q3 us-gaap Deferred Tax Assets In Process Research And Development
DeferredTaxAssetsInProcessResearchAndDevelopment
1575000 usd
CY2023Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
42000 usd
CY2023Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
9000 usd
CY2023Q4 us-gaap Assets
Assets
95502000 usd
CY2023Q3 us-gaap Assets
Assets
98829000 usd
CY2023Q4 us-gaap Notes Payable Current
NotesPayableCurrent
471000 usd
CY2023Q3 us-gaap Notes Payable Current
NotesPayableCurrent
333000 usd
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
325000 usd
CY2023Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
763000 usd
CY2023Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
115000 usd
CY2023Q3 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
1023000 usd
CY2023Q4 rfl Due To Related Parties
DueToRelatedParties
23000 usd
CY2023Q3 rfl Due To Related Parties
DueToRelatedParties
26000 usd
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
934000 usd
CY2023Q3 us-gaap Liabilities Current
LiabilitiesCurrent
2145000 usd
CY2023Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
56000 usd
CY2023Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
55000 usd
CY2023Q4 us-gaap Liabilities
Liabilities
990000 usd
CY2023Q3 us-gaap Liabilities
Liabilities
2200000 usd
CY2023Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
265487000 usd
CY2023Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
264010000 usd
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-170971000 usd
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-167333000 usd
CY2023Q4 us-gaap Treasury Stock Common Value
TreasuryStockCommonValue
79000 usd
CY2023Q4 us-gaap Accumulated Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-146000 usd
CY2023Q3 us-gaap Accumulated Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-353000 usd
CY2023Q4 us-gaap Accumulated Other Comprehensive Income Loss Foreign Currency Translation Adjustment Net Of Tax
AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax
3668000 usd
CY2023Q3 us-gaap Accumulated Other Comprehensive Income Loss Foreign Currency Translation Adjustment Net Of Tax
AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax
3725000 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
98205000 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
100293000 usd
CY2023Q4 us-gaap Minority Interest
MinorityInterest
-3693000 usd
CY2023Q3 us-gaap Minority Interest
MinorityInterest
-3664000 usd
CY2023Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
94512000 usd
CY2023Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
96629000 usd
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
95502000 usd
CY2023Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
98829000 usd
CY2023Q4 us-gaap Revenues
Revenues
68000 usd
CY2022Q4 us-gaap Revenues
Revenues
70000 usd
CY2023Q4 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2040000 usd
CY2022Q4 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3109000 usd
CY2023Q4 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
489000 usd
CY2022Q4 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2081000 usd
CY2023Q4 us-gaap Depreciation And Amortization
DepreciationAndAmortization
17000 usd
CY2022Q4 us-gaap Depreciation And Amortization
DepreciationAndAmortization
22000 usd
CY2023Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
-2478000 usd
CY2022Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
-5142000 usd
CY2023Q4 us-gaap Interest Income Other
InterestIncomeOther
582000 usd
CY2022Q4 us-gaap Interest Income Other
InterestIncomeOther
208000 usd
CY2022Q4 rfl Impairment Of Cost Method Investment Rafael Pharmaceuticals
ImpairmentOfCostMethodInvestmentRafaelPharmaceuticals
156000 usd
CY2023Q4 us-gaap Marketable Securities Realized Gain Loss Excluding Other Than Temporary Impairments
MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments
177000 usd
CY2022Q4 us-gaap Marketable Securities Realized Gain Loss Excluding Other Than Temporary Impairments
MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments
15000 usd
CY2023Q4 us-gaap Realized Investment Gains Losses
RealizedInvestmentGainsLosses
-46000 usd
CY2023Q4 us-gaap Other Income
OtherIncome
93000 usd
CY2023Q4 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-3538000 usd
CY2022Q4 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-5202000 usd
CY2023Q4 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
6000 usd
CY2022Q4 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
5000 usd
CY2023Q4 rfl Equity In Losses Of Day Three Labs Inc
EquityInLossesOfDayThreeLabsInc
216000 usd
CY2023Q4 us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-3760000 usd
CY2022Q4 us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-5207000 usd
CY2022Q4 us-gaap Discontinued Operation Income Loss From Discontinued Operation During Phase Out Period Net Of Tax
DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodNetOfTax
-84000 usd
CY2022Q4 us-gaap Discontinued Operation Gain Loss On Disposal Of Discontinued Operation Net Of Tax
DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax
6784000 usd
CY2022Q4 us-gaap Income Loss From Discontinued Operations Net Of Tax
IncomeLossFromDiscontinuedOperationsNetOfTax
6700000 usd
CY2023Q4 us-gaap Profit Loss
ProfitLoss
-3760000 usd
CY2022Q4 us-gaap Profit Loss
ProfitLoss
1493000 usd
CY2023Q4 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-122000 usd
CY2022Q4 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-99000 usd
CY2023Q4 us-gaap Net Income Loss
NetIncomeLoss
-3638000 usd
CY2022Q4 us-gaap Net Income Loss
NetIncomeLoss
1592000 usd
CY2023Q4 us-gaap Profit Loss
ProfitLoss
-3760000 usd
CY2022Q4 us-gaap Profit Loss
ProfitLoss
1493000 usd
CY2023Q4 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
207000 usd
CY2022Q4 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
103000 usd
CY2023Q4 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
-76000 usd
CY2022Q4 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
-10000 usd
CY2023Q4 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-3629000 usd
CY2022Q4 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
1586000 usd
CY2023Q4 us-gaap Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
-119000 usd
CY2022Q4 us-gaap Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
-99000 usd
CY2023Q4 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-3510000 usd
CY2022Q4 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
1685000 usd
CY2023Q4 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-0.15
CY2022Q4 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-0.22
CY2022Q4 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Basic Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
0.29
CY2023Q4 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.15
CY2022Q4 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.07
CY2023Q4 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
23644647 shares
CY2022Q4 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
23015443 shares
CY2023Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
96629000 usd
CY2023Q4 us-gaap Profit Loss
ProfitLoss
-3760000 usd
CY2023Q4 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
649000 usd
CY2023Q4 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
39000 usd
CY2023Q4 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
207000 usd
CY2023Q4 rfl Stock Issued During Period Units Value
StockIssuedDuringPeriodUnitsValue
925000 usd
CY2023Q4 rfl Purchases Of Treasury Stockin Shares
PurchasesOfTreasuryStockinShares
-79000 usd
CY2023Q4 us-gaap Stock Issued During Period Value Other
StockIssuedDuringPeriodValueOther
56000 usd
CY2023Q4 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-76000 usd
CY2023Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
94512000 usd
CY2022Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
97206000 usd
CY2022Q4 us-gaap Profit Loss
ProfitLoss
1493000 usd
CY2022Q4 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
1180000 usd
CY2022Q4 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
6000 usd
CY2022Q4 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
103000 usd
CY2022Q4 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-10000 usd
CY2022Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
99966000 usd
CY2023Q4 us-gaap Profit Loss
ProfitLoss
-3760000 usd
CY2022Q4 us-gaap Profit Loss
ProfitLoss
1493000 usd
CY2022Q4 us-gaap Income Loss From Discontinued Operations Net Of Tax
IncomeLossFromDiscontinuedOperationsNetOfTax
6700000 usd
CY2023Q4 us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-3760000 usd
CY2022Q4 us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-5207000 usd
CY2023Q4 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
17000 usd
CY2022Q4 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
22000 usd
CY2023Q4 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
27000 usd
CY2023Q4 rfl Gain Loss On Investments Hedge Fund
GainLossOnInvestmentsHedgeFund
-166000 usd
CY2022Q4 rfl Gain Loss On Investments Hedge Fund
GainLossOnInvestmentsHedgeFund
-127000 usd
CY2023Q4 us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
-46000 usd
CY2023Q4 us-gaap Marketable Securities Realized Gain Loss Excluding Other Than Temporary Impairments
MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments
177000 usd
CY2022Q4 us-gaap Marketable Securities Realized Gain Loss Excluding Other Than Temporary Impairments
MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments
15000 usd
CY2023Q4 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
-519000 usd
CY2022Q4 rfl Impairment Of Cost Method Investment Rafael Pharmaceuticals
ImpairmentOfCostMethodInvestmentRafaelPharmaceuticals
156000 usd
CY2023Q4 rfl Realized Gain In Equity Investments Cyclo Therapeutics Inc
RealizedGainInEquityInvestmentsCycloTherapeuticsInc
424000 usd
CY2023Q4 rfl Unrealized Loss In Equity Investments Cyclo Therapeutics Inc
UnrealizedLossInEquityInvestmentsCycloTherapeuticsInc
2124000 usd
CY2023Q4 rfl Gain On Dissolution Of A Business
GainOnDissolutionOfABusiness
18000 usd
CY2023Q4 rfl Equity In Loss Of Day Three Labs Inc2
EquityInLossOfDayThreeLabsInc2
216000 usd
CY2023Q4 us-gaap Provision For Other Losses
ProvisionForOtherLosses
2000 usd
CY2023Q4 us-gaap Share Based Compensation
ShareBasedCompensation
649000 usd
CY2022Q4 us-gaap Share Based Compensation
ShareBasedCompensation
1180000 usd
CY2023Q4 us-gaap Increase Decrease In Accounts And Other Receivables
IncreaseDecreaseInAccountsAndOtherReceivables
18000 usd
CY2022Q4 us-gaap Increase Decrease In Accounts And Other Receivables
IncreaseDecreaseInAccountsAndOtherReceivables
28000 usd
CY2023Q4 us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
33000 usd
CY2022Q4 us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
31000 usd
CY2023Q4 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-796000 usd
CY2022Q4 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-566000 usd
CY2023Q4 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
33000 usd
CY2022Q4 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
28000 usd
CY2023Q4 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-266000 usd
CY2022Q4 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
1017000 usd
CY2023Q4 us-gaap Increase Decrease In Other Current Liabilities
IncreaseDecreaseInOtherCurrentLiabilities
-908000 usd
CY2022Q4 us-gaap Increase Decrease In Other Current Liabilities
IncreaseDecreaseInOtherCurrentLiabilities
103000 usd
CY2023Q4 rfl Increase Decrease In Due From Rafael Pharmaceuticals
IncreaseDecreaseInDueFromRafaelPharmaceuticals
3000 usd
CY2022Q4 rfl Increase Decrease In Due From Rafael Pharmaceuticals
IncreaseDecreaseInDueFromRafaelPharmaceuticals
25000 usd
CY2023Q4 us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
1000 usd
CY2022Q4 us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
4000 usd
CY2023Q4 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-2133000 usd
CY2022Q4 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-2159000 usd
CY2022Q4 us-gaap Cash Provided By Used In Operating Activities Discontinued Operations
CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations
-421000 usd
CY2023Q4 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-2133000 usd
CY2022Q4 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-2580000 usd
CY2023Q4 us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
47525000 usd
CY2022Q4 us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
57119000 usd
CY2023Q4 us-gaap Proceeds From Sale Of Held To Maturity Securities
ProceedsFromSaleOfHeldToMaturitySecurities
47462000 usd
CY2022Q4 us-gaap Proceeds From Sale Of Held To Maturity Securities
ProceedsFromSaleOfHeldToMaturitySecurities
22922000 usd
CY2023Q4 us-gaap Payments For Proceeds From Loans Receivable
PaymentsForProceedsFromLoansReceivable
250000 usd
CY2023Q4 rfl Proceeds From Investments Other Pharmaceuticals
ProceedsFromInvestmentsOtherPharmaceuticals
42000 usd
CY2023Q4 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
271000 usd
CY2023Q4 rfl Purchase Of Investment In Cyclo Therapeutics Inc
PurchaseOfInvestmentInCycloTherapeuticsInc
6786000 usd
CY2023Q4 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-6786000 usd
CY2022Q4 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-34197000 usd
CY2022Q4 rfl Proceeds From Sale Of520 Property Discontinued Operations
ProceedsFromSaleOf520PropertyDiscontinuedOperations
49400000 usd
CY2022Q4 rfl Payment To Fund Rp Finance Line Of Credit
PaymentToFundRPFinanceLineOfCredit
1229000 usd
CY2022Q4 us-gaap Cash Provided By Used In Investing Activities Discontinued Operations
CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations
48171000 usd
CY2023Q4 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-6786000 usd
CY2022Q4 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
13974000 usd
CY2023Q4 rfl Payments For Taxes Related To Shares Withheld For Employee Taxes
PaymentsForTaxesRelatedToSharesWithheldForEmployeeTaxes
39000 usd
CY2022Q4 rfl Payments For Taxes Related To Shares Withheld For Employee Taxes
PaymentsForTaxesRelatedToSharesWithheldForEmployeeTaxes
6000 usd
CY2023Q4 us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
79000 usd
CY2023Q4 rfl Proceeds From Sale Of Rmd Membership Units
ProceedsFromSaleOfRMDMembershipUnits
925000 usd
CY2023Q4 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
807000 usd
CY2022Q4 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
-6000 usd
CY2022Q4 rfl Payment Of Note Payable In Connection With Sale Of520 Property Discontinued Operations
PaymentOfNotePayableInConnectionWithSaleOf520PropertyDiscontinuedOperations
15000000 usd
CY2022Q4 us-gaap Cash Provided By Used In Financing Activities Discontinued Operations
CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations
-15000000 usd
CY2023Q4 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
807000 usd
CY2022Q4 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-15006000 usd
CY2023Q4 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-189000 usd
CY2022Q4 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-92000 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-8301000 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-3704000 usd
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
21498000 usd
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
26537000 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
13197000 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
22833000 usd
CY2023Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
13197000 usd
CY2022Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
22173000 usd
CY2022Q4 us-gaap Restricted Cash
RestrictedCash
660000 usd
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
13197000 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
22833000 usd
CY2022Q4 rfl Transaction Costs Related To Sale Of520 Property Included In Accounts Payable
TransactionCostsRelatedToSaleOf520PropertyIncludedInAccountsPayable
43000 usd
CY2023Q4 us-gaap Noncash Or Part Noncash Divestiture Amount Of Consideration Received1
NoncashOrPartNoncashDivestitureAmountOfConsiderationReceived1
34000 usd
CY2023Q4 rfl Withdrawal Receivable From Hedge Funds Included In Other Current Assets
WithdrawalReceivableFromHedgeFundsIncludedInOtherCurrentAssets
2500000000 usd
CY2023Q1 us-gaap Debt Current
DebtCurrent
2000000 usd
CY2023Q4 us-gaap Sale Of Stock Percentage Of Ownership Before Transaction
SaleOfStockPercentageOfOwnershipBeforeTransaction
0.42 pure
CY2023Q3 us-gaap Other Ownership Interests Value
OtherOwnershipInterestsValue
925000000 usd
CY2023Q3 us-gaap Customer Funds
CustomerFunds
825000 usd
CY2023Q4 us-gaap Use Of Estimates
UseOfEstimates
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Use of Estimates    </i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the balance sheet and the reported amounts of revenue and expenses during the reporting periods. Actual results could differ significantly from those estimates.</p>
CY2023Q4 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
13200000 usd
CY2023Q4 us-gaap Assets Held For Sale Not Part Of Disposal Group Current Other
AssetsHeldForSaleNotPartOfDisposalGroupCurrentOther
58900000 usd
CY2023Q4 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><i>Concentration of Credit Risk and Significant Customers </i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company routinely assesses the financial strength of its customers. As a result, the Company believes that its accounts receivable credit risk exposure is limited. For the three months ended October 31, 2023, related parties represented 40% of the Company’s revenue. For the three months ended October 31, 2022, including revenue from discontinued operations, related parties represented 44% of the Company’s revenue, and as of October 31, 2022, one customer represented 67% of the Company’s accounts receivable balance.</p>
CY2022Q3 us-gaap Property Plant And Equipment Owned Gross
PropertyPlantAndEquipmentOwnedGross
49400000 usd
CY2023Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Purchase Price Of Common Stock Percent
SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
0.40 pure
CY2023Q4 us-gaap Debt And Equity Securities Unrealized Gain Loss
DebtAndEquitySecuritiesUnrealizedGainLoss
2100000 usd
CY2023Q4 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.50 pure
CY2023Q4 rfl Total Aggregate Fair Value
TotalAggregateFairValue
9849042000 usd
CY2023Q3 rfl Total Aggregate Fair Value
TotalAggregateFairValue
4763102000 usd
CY2023Q4 us-gaap Discontinued Operation Gain Loss On Disposal Of Discontinued Operation Net Of Tax
DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax
usd
CY2023Q4 us-gaap Income Loss From Discontinued Operations Net Of Tax
IncomeLossFromDiscontinuedOperationsNetOfTax
usd
CY2022Q3 us-gaap Proceeds From Sale Of Property Held For Sale
ProceedsFromSaleOfPropertyHeldForSale
49400000 usd
CY2023Q4 us-gaap Other Notes Payable
OtherNotesPayable
15000000 usd
CY2023Q4 us-gaap Proceeds From Repayments Of Notes Payable
ProceedsFromRepaymentsOfNotesPayable
33000000 usd
CY2023Q4 us-gaap Discontinued Operation Gain Loss From Disposal Of Discontinued Operation Before Income Tax
DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax
6800000 usd
CY2023Q4 us-gaap Proceeds From Sale Of Property Held For Sale
ProceedsFromSaleOfPropertyHeldForSale
49400000 usd
CY2023Q4 us-gaap Carrying Costs Property And Exploration Rights
CarryingCostsPropertyAndExplorationRights
40200000 usd
CY2023Q4 us-gaap Other Restructuring Costs
OtherRestructuringCosts
1200000 usd
CY2023Q4 us-gaap Deferred Rent Receivables Net
DeferredRentReceivablesNet
1200000 usd
CY2023Q4 us-gaap Proceeds From Sale Of Equity Method Investments
ProceedsFromSaleOfEquityMethodInvestments
44000000 usd
CY2023Q4 rfl Percentage Of Consolidation Less Than Wholly Owned Subsidiary Parent Ownership Interest Changes Purchase Of Interest By Parent
PercentageOfConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangesPurchaseOfInterestByParent
0.50 pure
CY2023Q4 rfl Ownership Interest Percentage
OwnershipInterestPercentage
0.08 pure
CY2023Q1 us-gaap Impaired Financing Receivable With Related Allowance Unpaid Principal Balance
ImpairedFinancingReceivableWithRelatedAllowanceUnpaidPrincipalBalance
2000000 usd
CY2023Q2 us-gaap Accounts Payable Interest Bearing Interest Rate
AccountsPayableInterestBearingInterestRate
0.075 pure
CY2023Q4 us-gaap Related Party Transaction Rate
RelatedPartyTransactionRate
0.11 pure
CY2023Q4 srt Interest Bearing Liabilities Average Rate Paid
InterestBearingLiabilitiesAverageRatePaid
0.14 pure
CY2023Q4 rfl Promissory Note Interest Rate1
PromissoryNoteInterestRate1
0.18 pure
CY2023Q4 us-gaap Interest Income Interest Earning Asset
InterestIncomeInterestEarningAsset
91000 usd
CY2023Q4 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
2 pure
CY2023Q4 us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-0.16
CY2022Q4 us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-0.22
CY2023Q4 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Basic Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
CY2023Q4 rfl Percentage Of Issued And Outstanding Shares
PercentageOfIssuedAndOutstandingShares
0.12 pure
CY2023Q4 us-gaap Proceeds From Interest Received
ProceedsFromInterestReceived
0 usd
CY2023 us-gaap Proceeds From Interest Received
ProceedsFromInterestReceived
0 usd
CY2023Q4 us-gaap Debt Instrument Face Amount
DebtInstrumentFaceAmount
9375000 usd
CY2023Q3 us-gaap Debt Instrument Face Amount
DebtInstrumentFaceAmount
9375000 usd
CY2023Q4 rfl Ownership Interests
OwnershipInterests
0.375 pure
CY2023Q3 rfl Ownership Interests
OwnershipInterests
0.375 pure
CY2023Q4 rfl Issued And Outstanding Ordinary Shares Percentage
IssuedAndOutstandingOrdinarySharesPercentage
0.95 pure
CY2023Q1 us-gaap Investment Maturity Date
InvestmentMaturityDate
2021-09-01
CY2021Q3 us-gaap Investment Interest Rate
InvestmentInterestRate
0.15 pure
CY2021Q4 us-gaap Investment Maturity Date
InvestmentMaturityDate
2022-11-11
CY2023Q4 us-gaap Redeemable Noncontrolling Interest Equity Other Carrying Amount
RedeemableNoncontrollingInterestEquityOtherCarryingAmount
8000 usd
CY2023Q1 us-gaap Investment Owned Percent Of Net Assets
InvestmentOwnedPercentOfNetAssets
0.95 pure
CY2023Q1 us-gaap Redeemable Noncontrolling Interest Equity Other Carrying Amount
RedeemableNoncontrollingInterestEquityOtherCarryingAmount
16000 usd
CY2023Q4 us-gaap Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
250000000 usd
CY2023Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
250000000 usd
CY2023Q4 rfl Purchase Agreement Description
PurchaseAgreementDescription
The Company purchased from Cyclo (i) 2,514,970 common shares (the “Purchased Shares”) and (ii) a warrant to purchase 2,514,970 common shares with an exercise price of $0.71 per share (the “May Warrant”), at a combined purchase price equal to $0.835 per Purchased Share and May Warrant to purchase one share, for an aggregate purchase price of $2.1 million.
CY2023Q2 rfl Additional Shares
AdditionalShares
4000000 shares
CY2023Q2 rfl Warrant Purchase Shares
WarrantPurchaseShares
4000000 shares
CY2023Q2 rfl Aggregate Purchase Amount
AggregatePurchaseAmount
5000000000 usd
CY2023Q4 rfl Common Shares
CommonShares
2514970 shares
CY2023Q4 rfl Additional Shares
AdditionalShares
2766467 shares
CY2023Q4 rfl Amortized Cost
AmortizedCost
58898000 usd
CY2023Q4 rfl Gross Unrealized Gains
GrossUnrealizedGains
17000 usd
CY2023Q4 rfl Gross Unrealizedlosses
GrossUnrealizedlosses
-21000 usd
CY2023Q4 rfl Fair Value
FairValue
58894000 usd
CY2023 rfl Amortized Cost
AmortizedCost
57988000 usd
CY2023 rfl Gross Unrealized Gains
GrossUnrealizedGains
4386000 usd
CY2023 rfl Gross Unrealizedlosses
GrossUnrealizedlosses
-4660000 usd
CY2023 rfl Fair Value
FairValue
57714000 usd
CY2023Q4 us-gaap Debt Securities Available For Sale Accumulated Gross Unrealized Gain Loss Before Tax
DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTax
177000 usd
CY2022Q4 us-gaap Debt Securities Available For Sale Accumulated Gross Unrealized Gain Loss Before Tax
DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTax
15000 usd
CY2023Q4 us-gaap Other Assets
OtherAssets
72919000 usd
CY2023Q3 us-gaap Other Assets
OtherAssets
69676000 usd
CY2023Q3 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Value
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue
6905000 usd
CY2022Q3 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Value
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue
4764000 usd
CY2023Q4 rfl Withdrawal From Hedge Fund Investment
WithdrawalFromHedgeFundInvestment
2500000 usd
CY2023Q4 us-gaap Change In Unrealized Gain Loss On Hedged Item In Fair Value Hedge1
ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1
-166000 usd
CY2022Q4 us-gaap Change In Unrealized Gain Loss On Hedged Item In Fair Value Hedge1
ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1
-127000 usd
CY2023Q4 us-gaap Investments Fair Value Disclosure
InvestmentsFairValueDisclosure
1338000 usd
CY2023Q4 rfl Unrealized Loss On Cyclo Warrants
UnrealizedLossOnCycloWarrants
-248000 usd
CY2023Q4 us-gaap Convertible Debt
ConvertibleDebt
63000 usd
CY2023Q4 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Value
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue
5266000 usd
CY2022Q4 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Value
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue
4637000 usd
CY2022Q4 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Diluted Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
0.29
CY2023Q4 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Diluted Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
CY2022Q4 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.07
CY2023Q4 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.16
CY2023Q4 us-gaap Investment Owned At Fair Value
InvestmentOwnedAtFairValue
0 usd
CY2023Q3 us-gaap Investment Owned At Fair Value
InvestmentOwnedAtFairValue
65000 usd
CY2023Q4 us-gaap Accounts Receivable Gross
AccountsReceivableGross
251000 usd
CY2023Q3 us-gaap Accounts Receivable Gross
AccountsReceivableGross
247000 usd
CY2023Q4 rfl Accounts Receivable Related Party
AccountsReceivableRelatedParty
225000 usd
CY2023Q3 rfl Accounts Receivable Related Party
AccountsReceivableRelatedParty
211000 usd
CY2023Q4 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
245000 usd
CY2023Q3 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
245000 usd
CY2023Q4 us-gaap Accounts Receivable Net
AccountsReceivableNet
231000 usd
CY2023Q3 us-gaap Accounts Receivable Net
AccountsReceivableNet
213000 usd
CY2022Q4 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
23015443 shares
CY2023Q4 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
23644647 shares
CY2023Q4 us-gaap Income Loss From Discontinued Operations Net Of Tax
IncomeLossFromDiscontinuedOperationsNetOfTax
usd
CY2022Q4 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
usd
CY2022Q4 us-gaap Unrealized Gain Loss On Investments
UnrealizedGainLossOnInvestments
usd
CY2023Q4 rfl Stock Options Excluded From Anti Diluted
StockOptionsExcludedFromAntiDiluted
388409 shares
CY2022Q4 rfl Stock Options Excluded From Anti Diluted
StockOptionsExcludedFromAntiDiluted
1021277 shares
CY2023Q4 rfl Shares Issuable Upon Vesting Of Restricted Stock
SharesIssuableUponVestingOfRestrictedStock
855173 shares
CY2022Q4 rfl Shares Issuable Upon Vesting Of Restricted Stock
SharesIssuableUponVestingOfRestrictedStock
1461934 shares
CY2023Q4 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1243582 shares
CY2022Q4 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
2483211 shares
CY2023Q4 us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-3760000 usd
CY2022Q4 us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-5207000 usd
CY2023Q4 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-122000 usd
CY2022Q4 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-99000 usd
CY2023Q4 us-gaap Noncontrolling Interest In Net Income Loss Other Noncontrolling Interests Redeemable
NoncontrollingInterestInNetIncomeLossOtherNoncontrollingInterestsRedeemable
-3638000 usd
CY2022Q4 us-gaap Noncontrolling Interest In Net Income Loss Other Noncontrolling Interests Redeemable
NoncontrollingInterestInNetIncomeLossOtherNoncontrollingInterestsRedeemable
-5108000 usd
CY2022Q4 us-gaap Income Loss From Discontinued Operations Net Of Tax
IncomeLossFromDiscontinuedOperationsNetOfTax
6700000 usd
CY2023Q4 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-3638000 usd
CY2022Q4 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
1592000 usd
CY2023Q4 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
23644647 shares
CY2022Q4 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
23015443 shares
CY2023Q4 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-0.15
CY2022Q4 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-0.22
CY2022Q4 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Basic Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
0.29
CY2023Q4 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.15
CY2022Q4 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.07
CY2022Q4 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
usd
CY2023Q4 rfl Impairment Of Cost Method Investment Rafael Pharmaceuticals
ImpairmentOfCostMethodInvestmentRafaelPharmaceuticals
usd
CY2022Q4 rfl Realized Gain In Equity Investments Cyclo Therapeutics Inc
RealizedGainInEquityInvestmentsCycloTherapeuticsInc
usd
CY2022Q4 rfl Unrealized Loss In Equity Investments Cyclo Therapeutics Inc
UnrealizedLossInEquityInvestmentsCycloTherapeuticsInc
usd
CY2023Q4 us-gaap Costs And Expenses Related Party
CostsAndExpensesRelatedParty
78000 usd
CY2023 us-gaap Costs And Expenses Related Party
CostsAndExpensesRelatedParty
313000 usd
CY2023Q4 us-gaap Related Party Tax Expense Due To Affiliates Current
RelatedPartyTaxExpenseDueToAffiliatesCurrent
78000 usd
CY2023 us-gaap Related Party Tax Expense Due To Affiliates Current
RelatedPartyTaxExpenseDueToAffiliatesCurrent
70000 usd
CY2023Q4 us-gaap Area Of Land
AreaOfLand
80000 sqft
CY2023Q4 us-gaap Discontinued Operation Tax Effect Of Discontinued Operation
DiscontinuedOperationTaxEffectOfDiscontinuedOperation
27000 usd
CY2023Q2 us-gaap Interest Receivable
InterestReceivable
2000000 usd
CY2023Q2 us-gaap Long Term Debt Maturity Date
LongTermDebtMaturityDate
2023-11-30
CY2022Q4 us-gaap Cash Including Discontinued Operations
CashIncludingDiscontinuedOperations
19000 usd
CY2023Q4 us-gaap Payments For Leasing Costs
PaymentsForLeasingCosts
20000 usd
CY2023Q4 rfl Revenue Percentage
RevenuePercentage
0.40 pure
CY2022Q4 rfl Revenue Percentage
RevenuePercentage
0.44 pure
CY2020Q4 us-gaap Sale Of Stock Consideration Received On Transaction
SaleOfStockConsiderationReceivedOnTransaction
5000000 usd
CY2020Q4 rfl Warrants Percentage
WarrantsPercentage
0.20 pure
CY2022Q3 us-gaap Stockholders Equity Other Shares
StockholdersEquityOtherShares
3225806 shares
CY2022Q3 rfl Aggregate Price Per Share
AggregatePricePerShare
1.86
CY2022Q3 rfl Aggregtae Sale Price
AggregtaeSalePrice
6000000 usd
CY2023Q3 rfl Aggregate Voting Percentage
AggregateVotingPercentage
0.513 pure
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Shares Purchased For Award
ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward
70000000 shares
CY2023Q1 us-gaap Shares Issued Price Per Share
SharesIssuedPricePerShare
0.03
CY2023Q1 rfl Amount Of Aggregate Purchase Price
AmountOfAggregatePurchasePrice
2100000 usd
CY2023Q1 us-gaap Short Term Debt Interest Rate Increase
ShortTermDebtInterestRateIncrease
0.95 pure
CY2023Q1 us-gaap Redeemable Noncontrolling Interest Equity Carrying Amount
RedeemableNoncontrollingInterestEquityCarryingAmount
16000 usd
CY2023Q4 us-gaap Income Tax Expense Benefit Continuing Operations Adjustment Of Deferred Tax Asset Liability
IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability
6000 usd
CY2022Q4 us-gaap Income Tax Expense Benefit Continuing Operations Adjustment Of Deferred Tax Asset Liability
IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability
5000 usd
CY2023Q4 us-gaap Income Loss Attributable To Parent
IncomeLossAttributableToParent
3500000 usd
CY2022Q4 us-gaap Income Loss Attributable To Parent
IncomeLossAttributableToParent
5200000 usd
CY2023Q4 us-gaap Revenue Remaining Performance Obligation Percentage
RevenueRemainingPerformanceObligationPercentage
1 pure
CY2022Q4 us-gaap Revenue Remaining Performance Obligation Percentage
RevenueRemainingPerformanceObligationPercentage
0.22 pure
CY2023Q2 us-gaap Stock Repurchase Program Authorized Amount1
StockRepurchaseProgramAuthorizedAmount1
5000000 usd
CY2023Q2 us-gaap Sale Of Stock Price Per Share
SaleOfStockPricePerShare
1.75
CY2023Q3 us-gaap Stock Repurchase Program Authorized Amount1
StockRepurchaseProgramAuthorizedAmount1
5000000 usd
CY2023Q3 us-gaap Sale Of Stock Price Per Share
SaleOfStockPricePerShare
1.75
CY2023Q4 rfl Restricted Stock Units Description
RestrictedStockUnitsDescription
On August 24, 2021, the Company issued 2,833,425 shares of Class B common stock (the "Institutional Shares"), par value $0.01 per share, to the Institutional Investors, at a purchase price equal to $35.00 per share, for aggregate gross proceeds of approximately $99.2 million, before deducting placement agent fees and other offering expenses.
CY2023Q4 us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
98000000 usd
CY2023Q4 rfl Deducting Transaction Costs
DeductingTransactionCosts
6200000 usd
CY2022Q3 rfl Aggregate Sale Price
AggregateSalePrice
6000000 usd
CY2022Q2 rfl Employment Agreement Term
EmploymentAgreementTerm
P5Y
CY2022Q2 us-gaap Common Stock Value Outstanding
CommonStockValueOutstanding
600000000 usd
CY2022Q3 us-gaap Labor And Related Expense
LaborAndRelatedExpense
290000000 usd
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
684766 shares
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
4.22
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
246408 shares
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
388409 shares
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
14.51
CY2023Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y8M15D
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
388409 shares
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
14.51
CY2023Q4 rfl Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm
P8Y5M12D
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
115800 shares
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
27.76
CY2023Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P7Y8M23D
CY2023Q4 us-gaap Conversion Of Stock Shares Issued1
ConversionOfStockSharesIssued1
46125 shares
CY2023Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
246000 usd
CY2023Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P3Y9M18D
CY2022Q1 us-gaap Stock Issued During Period Shares Restricted Stock Award Gross
StockIssuedDuringPeriodSharesRestrictedStockAwardGross
33360 shares
CY2022Q1 us-gaap Restricted Stock Shares Issued Net Of Shares For Tax Withholdings
RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings
986835 shares
CY2022Q1 rfl Restricted Shares Vested Percentage
RestrictedSharesVestedPercentage
0.24 pure
CY2022Q2 us-gaap Restricted Stock Shares Issued Net Of Shares For Tax Withholdings
RestrictedStockSharesIssuedNetOfSharesForTaxWithholdings
452130 shares
CY2023 us-gaap Selling Expense
SellingExpense
307913000 usd
CY2023Q4 us-gaap Stock Issued During Period Value Share Based Compensation Forfeited
StockIssuedDuringPeriodValueShareBasedCompensationForfeited
915000 usd
CY2023Q3 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
111408 shares
CY2023Q4 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
135000 shares
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
1.84
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
76001 shares
CY2023Q4 rfl Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Option Vested In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionVestedInPeriodWeightedAverageGrantDateFairValue
4.03
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
855173 shares
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
3.41
CY2023Q4 rfl Forfeiture Of Rs Us Within General And Administrative
ForfeitureOfRSUsWithinGeneralAndAdministrative
508000 usd
CY2022Q4 rfl Forfeiture Of Rs Us Within General And Administrative
ForfeitureOfRSUsWithinGeneralAndAdministrative
1083000 usd
CY2023Q4 rfl Forfeiture Of Rs Us Within Research And Development
ForfeitureOfRSUsWithinResearchAndDevelopment
141000 usd
CY2022Q4 rfl Forfeiture Of Rs Us Within Research And Development
ForfeitureOfRSUsWithinResearchAndDevelopment
97000 usd
CY2023Q4 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
649000 usd
CY2022Q4 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1180000 usd
CY2023Q4 us-gaap Warrant Exercise Price Decrease
WarrantExercisePriceDecrease
22.91
CY2023Q4 rfl Lease Expiration Dates
LeaseExpirationDates
The Company is the lessor of the Israeli property which is leased to tenants under net operating leases with a term expiration date within 2025.
CY2023Q4 rfl Comprehensive Income Loss Net Of Tax Attributable To Noncontrolling Interests
ComprehensiveIncomeLossNetOfTaxAttributableToNoncontrollingInterests
100000 usd
CY2022Q4 rfl Comprehensive Income Loss Net Of Tax Attributable To Noncontrolling Interests
ComprehensiveIncomeLossNetOfTaxAttributableToNoncontrollingInterests
100000 usd
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
58000 usd
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
78000 usd
CY2023Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
136000 usd
CY2023Q4 us-gaap Related Party Transaction Description Of Transaction
RelatedPartyTransactionDescriptionOfTransaction
A related party has the right to terminate the Israeli lease upon four months’ notice.
CY2022Q4 us-gaap Realized Investment Gains Losses
RealizedInvestmentGainsLosses
usd
CY2022Q4 us-gaap Other Income
OtherIncome
usd
CY2022Q4 rfl Gain On Dissolution Of A Business
GainOnDissolutionOfABusiness
usd
CY2022Q4 rfl Equity In Loss Of Day Three Labs Inc2
EquityInLossOfDayThreeLabsInc2
usd
CY2022Q4 us-gaap Provision For Other Losses
ProvisionForOtherLosses
usd
CY2023Q4 us-gaap Cash Provided By Used In Operating Activities Discontinued Operations
CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations
usd
CY2022Q4 us-gaap Payments For Proceeds From Loans Receivable
PaymentsForProceedsFromLoansReceivable
usd
CY2022Q4 rfl Proceeds From Investments Other Pharmaceuticals
ProceedsFromInvestmentsOtherPharmaceuticals
usd
CY2022Q4 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
usd
CY2022Q4 rfl Purchase Of Investment In Cyclo Therapeutics Inc
PurchaseOfInvestmentInCycloTherapeuticsInc
usd
CY2023Q4 rfl Proceeds From Sale Of520 Property Discontinued Operations
ProceedsFromSaleOf520PropertyDiscontinuedOperations
usd
CY2023Q4 rfl Payment To Fund Rp Finance Line Of Credit
PaymentToFundRPFinanceLineOfCredit
usd
CY2023Q4 us-gaap Cash Provided By Used In Investing Activities Discontinued Operations
CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations
usd
CY2022Q4 us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
usd
CY2022Q4 rfl Proceeds From Sale Of Rmd Membership Units
ProceedsFromSaleOfRMDMembershipUnits
usd
CY2023Q4 rfl Payment Of Note Payable In Connection With Sale Of520 Property Discontinued Operations
PaymentOfNotePayableInConnectionWithSaleOf520PropertyDiscontinuedOperations
usd
CY2023Q4 us-gaap Cash Provided By Used In Financing Activities Discontinued Operations
CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations
usd
CY2023Q4 us-gaap Restricted Cash
RestrictedCash
usd
CY2023Q4 rfl Transaction Costs Related To Sale Of520 Property Included In Accounts Payable
TransactionCostsRelatedToSaleOf520PropertyIncludedInAccountsPayable
usd
CY2022Q4 us-gaap Noncash Or Part Noncash Divestiture Amount Of Consideration Received1
NoncashOrPartNoncashDivestitureAmountOfConsiderationReceived1
usd
CY2022Q4 rfl Withdrawal Receivable From Hedge Funds Included In Other Current Assets
WithdrawalReceivableFromHedgeFundsIncludedInOtherCurrentAssets
usd
CY2022Q4 rfl Withdrawal From Hedge Fund Investment
WithdrawalFromHedgeFundInvestment
usd
CY2022Q4 us-gaap Investments Fair Value Disclosure
InvestmentsFairValueDisclosure
usd
CY2022Q4 rfl Unrealized Loss On Cyclo Warrants
UnrealizedLossOnCycloWarrants
usd
CY2022Q4 us-gaap Convertible Debt
ConvertibleDebt
usd
CY2023Q4 us-gaap Income Loss From Discontinued Operations Net Of Tax
IncomeLossFromDiscontinuedOperationsNetOfTax
usd
CY2022Q4 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
23015443 shares
CY2023Q4 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
23644647 shares
CY2023Q4 us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-0.16
CY2022Q4 us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-0.22
CY2023Q4 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Basic Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
CY2022Q4 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Diluted Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
0.29
CY2023Q4 us-gaap Income Loss From Discontinued Operations Net Of Tax Per Diluted Share
IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
CY2022Q4 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.07
CY2023Q4 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.16
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
usd
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
shares
CY2023Q4 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
CY2023Q4 rfl Weighted Average Remaining Contractual Termin Years Granted
WeightedAverageRemainingContractualTerminYearsGranted
CY2023Q4 rfl Aggregate Intrinsic Value Outstanding Granted
AggregateIntrinsicValueOutstandingGranted
usd
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
shares
CY2023Q4 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
CY2023Q4 rfl Share Based Compensation Weighted Average Remaining Contractual Termin Years Expired
ShareBasedCompensationWeightedAverageRemainingContractualTerminYearsExpired
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
usd
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
shares
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
CY2023Q4 rfl Weighted Average Remaining Contractual Termin Years Cancelled Forfeited
WeightedAverageRemainingContractualTerminYearsCancelledForfeited
CY2023Q4 rfl Aggregate Intrinsic Value Cancelled Forfeited
AggregateIntrinsicValueCancelledForfeited
usd
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
usd
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
usd
CY2023Q4 dei Amendment Flag
AmendmentFlag
false
CY2023Q4 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--07-31
CY2023Q4 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2023Q4 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
CY2023Q4 dei Entity Central Index Key
EntityCentralIndexKey
0001713863

Files In Submission

Name View Source Status
0001213900-23-095748-index-headers.html Edgar Link pending
0001213900-23-095748-index.html Edgar Link pending
0001213900-23-095748.txt Edgar Link pending
0001213900-23-095748-xbrl.zip Edgar Link pending
f10q1023ex31-1_rafaelhold.htm Edgar Link pending
f10q1023ex31-2_rafaelhold.htm Edgar Link pending
f10q1023ex32-1_rafaelhold.htm Edgar Link pending
f10q1023ex32-2_rafaelhold.htm Edgar Link pending
f10q1023_rafaelhold.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
f10q1023_rafaelhold_htm.xml Edgar Link completed
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R72.htm Edgar Link pending
R73.htm Edgar Link pending
R74.htm Edgar Link pending
R75.htm Edgar Link pending
R76.htm Edgar Link pending
R77.htm Edgar Link pending
R78.htm Edgar Link pending
R79.htm Edgar Link pending
R8.htm Edgar Link pending
R80.htm Edgar Link pending
R81.htm Edgar Link pending
R82.htm Edgar Link pending
R83.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
rfl-20231031.xsd Edgar Link pending
Show.js Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
rfl-20231031_def.xml Edgar Link unprocessable
rfl-20231031_lab.xml Edgar Link unprocessable
rfl-20231031_pre.xml Edgar Link unprocessable
rfl-20231031_cal.xml Edgar Link unprocessable